Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025

Description

Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation and damage resulting from the accumulation of fat in the liver. NASH biomarkers serve as diagnostic tools to evaluate the severity of non-alcoholic steatohepatitis and assess liver damage. This condition can lead to inflammation and damage to liver cells, potentially causing cirrhosis (liver scarring) and liver failure. Biomarkers, in this context, are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.

The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.36 billion in 2024 to $1.7 billion in 2025 at a compound annual growth rate (CAGR) of 24.8%. The growth in the historic period can be attributed to diabetes and metabolic syndrome, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in NASH.

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.86 billion in 2029 at a compound annual growth rate (CAGR) of 22.8%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (AI), inclusion of imaging biomarkers.

The increasing incidence of liver cancer is anticipated to drive the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers market in the future. Liver cancer involves the formation of malignant tumors in the liver, which can originate in the liver itself (primary liver cancer) or spread from other areas of the body (secondary or metastatic liver cancer). NASH biomarkers are utilized in liver cancer for early detection, monitoring disease progression, and evaluating treatment response, providing prognostic information while potentially reducing the necessity for invasive procedures. For example, in 2022, the World Cancer Research Fund, a UK-based non-profit organization, reported approximately 866,136 new liver cancer cases globally, ranking it as the sixth most common cancer worldwide. As a result, the rising prevalence of liver cancer is fueling the growth of the non-alcoholic steatohepatitis biomarkers market.

The increasing demand for personalized medicine is poised to fuel the growth of the non-alcoholic steatohepatitis biomarkers market. Personalized medicine involves tailoring medical decisions, interventions, and drug therapies to individual patients. In the context of non-alcoholic steatohepatitis (NASH) biomarkers, personalized medicine facilitates precise and individualized diagnosis, the development of tailored treatment strategies, optimized drug selection, treatment response monitoring, and minimization of adverse effects. Reports from October 2022 indicate over 75,000 genetic testing products and 300 personalized medicines, highlighting the growing demand for personalized medicine and its role in driving the non-alcoholic steatohepatitis biomarkers market.

Technological advancements have emerged as a prominent trend in the non-alcoholic steatohepatitis biomarkers market, with major companies focusing on innovative solutions to enhance their market position. In October 2022, GENFIT and LabCorp entered a five-year exclusive licensing deal for GENFIT's NIS4 technology, a multi-biomarker-based algorithm designed to identify patients at risk of non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis. LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada. This partnership aims to provide widespread access to healthcare professionals, demonstrating the importance of technological advancements in driving the non-alcoholic steatohepatitis biomarkers market.

Key companies in the non-alcoholic steatohepatitis (NASH) biomarkers market are concentrating on implementing Enhanced Liver Fibrosis (ELF) tests to enhance the diagnosis and monitoring of liver fibrosis, a critical aspect of NASH. The ELF Test is a blood-based diagnostic tool designed to evaluate the prognosis for patients with advanced fibrosis (F3 or F4) resulting from non-alcoholic steatohepatitis, which is a form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation. For instance, in January 2022, Siemens Healthineers, a Germany-based company, introduced the Enhanced Liver Fibrosis (ELF) Test. This test was the first blood test to receive De Novo marketing authorization from the FDA specifically for assessing disease progression in NASH patients. By using a simple blood sample, the ELF Test evaluates three biomarkers linked to liver fibrosis: hyaluronic acid, tissue inhibitor of metalloproteinases 1 (TIMP-1), and aminoterminal propeptide of type III procollagen (P3NP). This method eliminates the need for invasive procedures, such as liver biopsies. The test is widely available through partnerships with Labcorp and Quest Diagnostics, ensuring accessibility for patients and healthcare providers throughout the U.S.

In June 2022, Novo Nordisk A/S partnered with Echosens SA to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise awareness among patients, medical professionals, and other stakeholders. Echosens SA, a France-based manufacturer, specializes in therapeutic monitoring and diagnostic devices.

Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Hepatic Fibrosis Biomarkers; Serum Biomarkers; Oxidative Stress Biomarkers; Apoptosis Biomarkers; Other Types
2) By Disease: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
3) By End Use: Research Institutes And Academics; Diagnostic Centers; Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs); Hospitals And Clinics; Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid; Procollagen III N-terminal Propeptide (PIIINP); Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT); Aspartate Aminotransferase (AST); Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA); 8-Isoprostane; Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3; Cytochrome c; Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers; Genetic Biomarkers; Inflammatory Biomarkers
Companies Mentioned: Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23588

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis Biomarkers Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Alcoholic Steatohepatitis Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate Analysis
5.4. Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Alcoholic Steatohepatitis Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Alcoholic Steatohepatitis Biomarkers Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

6.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Other Types
6.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity
6.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Research Institutes And Academics
Diagnostic Centres
Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs)
Hospitals And Clinics
Other End-Uses
6.4. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Hepatic Fibrosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hyaluronic Acid
Procollagen III N-terminal Propeptide (PIIINP)
Fibrosis-4 (FIB-4) Index
6.5. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Serum Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alanine Aminotransferase (ALT)
Aspartate Aminotransferase (AST)
Adiponectin
6.6. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Oxidative Stress Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Malondialdehyde (MDA)
8-Isoprostane
Advanced Oxidation Protein Products (AOPP)
6.7. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Apoptosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Caspase-3
Cytochrome c
Liver Inhibitory Protein (LIP)
6.8. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metabolomic Biomarkers
Genetic Biomarkers
Inflammatory Biomarkers

7. Non-Alcoholic Steatohepatitis Biomarkers Market Regional And Country Analysis

7.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market

8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis Biomarkers Market

9.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Overview
9.2. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis Biomarkers Market

10.1. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Biomarkers Market

11.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Overview
11.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Biomarkers Market

12.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market

13.1. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market

14.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Overview
14.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market

15.1. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
15.2. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Biomarkers Market

16.1. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Biomarkers Market

17.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis Biomarkers Market

18.1. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Biomarkers Market

19.1. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Biomarkers Market

20.1. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market

21.1. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
21.2. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Biomarkers Market

22.1. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Biomarkers Market

23.1. North America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
23.2. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Biomarkers Market

24.1. USA Non-Alcoholic Steatohepatitis Biomarkers Market Overview
24.2. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Biomarkers Market

25.1. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Overview
25.2. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Biomarkers Market

26.1. South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
26.2. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

27.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

28.1. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Overview
28.2. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

29.1. Africa Non-Alcoholic Steatohepatitis Biomarkers Market Overview
29.2. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

30.1. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
30.2. Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
- 30.2.1. Genfit SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Prometheus Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Siemens Medical Solutions USA Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. BioPredictive Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis Biomarkers Market Other Major And Innovative Companies

31.1. AstraZeneca Plc.
31.2. Laboratory Corporation of America Holdings
31.3. Pfizer Inc.
31.4. Bristol-Myers Squibb Company
31.5. NGM Biopharmaceuticals Inc.
31.6. Gilead Sciences Inc.
31.7. Perspectum Diagnostics Ltd.
31.8. One Way Liver SL
31.9. Enterome SA
31.10. Echosens SA
31.11. Cisbio Bioassays SAS
31.12. Celerion Inc.
31.13. Boehringer Ingelheim GmbH Inc.
31.14. Exalenz Bioscience Ltd.
31.15. Novartis AG

32. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis Biomarkers Market

35. Non-Alcoholic Steatohepatitis Biomarkers Market High Potential Countries, Segments and Strategies

35.1 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer